NEWS


Date:2022-10-18

Press Release: CHO-H01 of CHO Pharma Won an Award of Excellence

 

 Press Release 2022.10.18

CHO-H01 of CHO Pharma Won an Award of Excellence

CHO Pharma’s CHO-H01 won “Most Promising Monoclonal Antibodies Pipeline” in Taiwan Biopharma Excellence Awards in the 10th Biological World Taiwan on October 18th and 19th, 2022.

President Wu stressed CHO-H01 is the very first glycoengineered antibody drug with a single human glycan form that has entered clinical trial. We are quite satisfied with its safety profiles and low immunogenicity property in lymphoma patients.

Press Release: Sparking Synergy! CHO Pharma and StemCyte Combine Antibody with Homogenous Glycan and Cell Therapy to Develop New Cancer Therapy.